AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The inhibitory effects of Ponatinib on individual downstream signal transduction pathways have been reported in various cellular systems, including ERK in multiple CML cell lines [65] and endometrial cancer cells [33], Akt in murine myeloid cells [30] and endometrial cancer cells [33], and p38 MAPK in murine macrophages [66].